Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Notice to: Smad7 suppresses renal fibrosis via altering expression of TGFβ/Smad3-regulated microRNAs.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

The Gut Microbiota in Young Adults with High-Functioning Autism Spectrum Disorder and Its Performance as Diagnostic Biomarkers.

Nutrients·2025
Same author

Long Non-coding RNA NEAT1 , NOD-Like Receptor Family Protein 3 Inflammasome, and Acute Kidney Injury.

Journal of the American Society of Nephrology : JASN·2024
Same author

Hypermethylation of <i>Smad7</i> in CD4<sup>+</sup> T cells is associated with the disease activity of rheumatoid arthritis.

Frontiers in immunology·2023
Same author

The long noncoding RNA Meg3 mediates TLR4-induced inflammation in experimental obstructive nephropathy.

Clinical science (London, England : 1979)·2023
Same author

Mass spectrometry imaging and monitoring of <i>in vivo</i> glutathione-triggered cisplatin release from nanoparticles in the kidneys.

Nanoscale advances·2022

Related Experiment Video

Updated: Jun 1, 2026

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Transforming growth factor-β and Smads.

Hui Yao Lan, Arthur C K Chung

    Contributions to Nephrology
    |June 11, 2011
    PubMed
    Summary

    Transforming growth factor-beta (TGF-β) signaling is crucial in diabetic nephropathy (DN). Targeting Smad7 shows promise for inhibiting renal fibrosis and improving kidney function in DN.

    Area of Science:

    • Nephrology
    • Endocrinology
    • Molecular Biology

    Background:

    • Diabetic nephropathy (DN) is a significant complication of diabetes.
    • Transforming growth factor-beta (TGF-β) is a key mediator in DN development.
    • TGF-β signaling involves Smad2/3 activation, Smad7 inhibition, and interactions with MAPK and NF-κB pathways.

    Purpose of the Study:

    • To explore the role of TGF-β/Smad signaling in diabetic nephropathy.
    • To investigate the impact of microRNAs on TGF-β signaling in DN.
    • To evaluate potential therapeutic strategies targeting TGF-β signaling in DN.

    Main Methods:

    • Review of recent studies on TGF-β/Smad signaling in DN.
    • Analysis of microRNA regulation by TGF-β and glucose in a diabetic context.

    More Related Videos

    Visualization and Quantification of TGF&#946;/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
    11:38

    Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

    Published on: September 14, 2021

    Live Cell Imaging of the TGF- &beta;/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
    11:06

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

    Published on: July 30, 2018

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
    06:54

    Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

    Published on: October 27, 2020

    Visualization and Quantification of TGF&#946;/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
    11:38

    Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

    Published on: September 14, 2021

    Live Cell Imaging of the TGF- &beta;/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
    11:06

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

    Published on: July 30, 2018

  • Examination of therapeutic approaches including antibodies, oligonucleotides, soluble receptors, and gene transfer of Smad7.

    • Main Results:

    • TGF-β/Smad signaling is central to DN pathogenesis.
    • Specific microRNAs (miR-192, miR-377, miR-29a) are dysregulated in DN and contribute to the condition.
    • Gene transfer of Smad7 effectively inhibits renal fibrosis and ameliorates kidney impairment in DN.

    Conclusions:

    • TGF-β/Smad signaling is a critical player in the development of diabetic nephropathy.
    • Modulating microRNA expression offers a potential therapeutic avenue for DN.
    • Further understanding of TGF-β/Smad signaling is essential for developing effective DN treatments.